Tubular Markers in Response to Saxagliptin Therapy
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Saxagliptin 5mg
Sponsored by

About this trial
This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring saxagliptin, uNGAL, u L-FABP, DKD
Eligibility Criteria
Inclusion Criteria:
- T2 DM,
- prevalent albuminuria (30-3000mg/g),
- controlled hypertension (defined as blood pressure <140/90 mm Hg) on a selected angiotensin receptor blocker, olmesartan 20mg/day for at least 4 weeks before intervention.
Exclusion Criteria:
- type 1 diabetes,
- poorly controlled hypertension (140-160/90-100 mm Hg),
- pancreatitis,
- malignancies
- albuminuria more than 3000mg/g.
- cardiovascular diseases (acute myocardial infarction, cerebrovascular disease in the past 6months,
- End Stage Renal Disease (ESRD) on chronic dialysis, renal transplant, a serum creatinine >6.0 mg/dL, or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2.
Sites / Locations
- Faculty of Pharmacy
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
saxagliptin
control
Arm Description
patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of <50 mL/min/1.73 m2
patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,
Outcomes
Primary Outcome Measures
to measure renal effect of saxagliptin on tubular markers
the rate of change of uNGAL and u LFABP markers would be estimated across the two time points after saxagliptin treatment .
to measure effect of saxagliptin on renal on albuminuria
the rate of change of UACR would be measured across the two time points after saxagliptin treatment
to classify renal responders to saxagliptin using tubular markers
patients would be classified into high risk and low risk patients according to their marker levels
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04521049
Brief Title
Tubular Markers in Response to Saxagliptin Therapy
Official Title
A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Patients With Diabetic Nephropathy
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
March 1, 2019 (Actual)
Primary Completion Date
March 1, 2020 (Actual)
Study Completion Date
April 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beni-Suef University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
the study aims to investigate whether treatment with saxagliptin would induce beneficial changes in renal NGAL and L-FABP biomarkers and if they would be used as a tool to identify patients' categories with a particular renal response to DPP-4inhibition. Secondly, to find an association between NGAL and L-FABP, and the relevant renal parameters for both baseline values and rate of changes across defined time points.
Detailed Description
Diabetic kidney disease (DKD) is considered a substantial cause of end-stage kidney disease (ESKD) worldwide. Incorporation of renoprotective options during interventions to prevent the development of DKD and attenuation of its progression; is of the utmost importance. Incretin-based therapies, specifically dipeptidyl peptidase 4 (DPP-4) inhibitors exhibited albuminuria lowering potential beyond their antihyperglycemic effects. Saxagliptin, a potent selective DPP-4 inhibitor which has been used as monotherapy or in combination with antidiabetics, has demonstrated great renal efficiency on both experimental and clinical scale .
Although albumin excretion rate (AER) is a powerful predictor of kidney function deterioration and progressive renal dysfunction, it is primarily a marker of glomerular damage and it has some drawbacks. For example; some patients may follow a non-albuminuric pathway to kidney impairment, others do not progress to macroalbuminuria but remain at microalbuminuria or even regress to normoalbuminuria. Thus, more sensitive and specific renal biomarkers than AER will be valuable in predicting early kidney injury and the progression of diabetic renal damage.
Besides glomerular damage, tubulointerstitial dysfunction largely contributes to the pathology of diabetic nephropathy. Neutrophil gelatinase-associated lipocalin (NGAL) and liver type fatty acid binding protein (L-FABP) are apparent as excellent biomarkers of tubular damage and are earlier predictors of acute kidney injury relative to microalbuminuria. NGAL is produced by neutrophils, highly expressed in tubular epithelium and released from tubular cells following damage . L-FABP is expressed in the proximal tubules and secreted into urine upon tubulointerstitial damage. Clinical significance of these biomarkers lies in their emergence in normoalbuminuric patients and their association with increased albuminuria and progression to ESRD with sustained high urinary markers' levels.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
saxagliptin, uNGAL, u L-FABP, DKD
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
80 (Actual)
8. Arms, Groups, and Interventions
Arm Title
saxagliptin
Arm Type
Active Comparator
Arm Description
patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of <50 mL/min/1.73 m2
Arm Title
control
Arm Type
No Intervention
Arm Description
patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,
Intervention Type
Drug
Intervention Name(s)
Saxagliptin 5mg
Other Intervention Name(s)
Onglyza
Intervention Description
Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR <50 mL/min/1.73 m2
Primary Outcome Measure Information:
Title
to measure renal effect of saxagliptin on tubular markers
Description
the rate of change of uNGAL and u LFABP markers would be estimated across the two time points after saxagliptin treatment .
Time Frame
3 months
Title
to measure effect of saxagliptin on renal on albuminuria
Description
the rate of change of UACR would be measured across the two time points after saxagliptin treatment
Time Frame
3 months
Title
to classify renal responders to saxagliptin using tubular markers
Description
patients would be classified into high risk and low risk patients according to their marker levels
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
T2 DM,
prevalent albuminuria (30-3000mg/g),
controlled hypertension (defined as blood pressure <140/90 mm Hg) on a selected angiotensin receptor blocker, olmesartan 20mg/day for at least 4 weeks before intervention.
Exclusion Criteria:
type 1 diabetes,
poorly controlled hypertension (140-160/90-100 mm Hg),
pancreatitis,
malignancies
albuminuria more than 3000mg/g.
cardiovascular diseases (acute myocardial infarction, cerebrovascular disease in the past 6months,
End Stage Renal Disease (ESRD) on chronic dialysis, renal transplant, a serum creatinine >6.0 mg/dL, or estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ahmed A Elberry, prof
Organizational Affiliation
Clinical Pharmacology Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt
Official's Role
Study Chair
Facility Information:
Facility Name
Faculty of Pharmacy
City
Al Qāhirah Al Jadīdah
ZIP/Postal Code
0004
Country
Egypt
12. IPD Sharing Statement
Learn more about this trial
Tubular Markers in Response to Saxagliptin Therapy
We'll reach out to this number within 24 hrs